COMMUNIQUÉS West-GlobeNewswire
-
TerrAscend to Host Second Quarter 2026 Earnings Conference Call
16/07/2026 -
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
16/07/2026 -
RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
16/07/2026 -
BioAdaptives® Outlines Xcellara™ Platform Strategy: Integrating Stem Cell Supply and Direction for Targeted Wellness
16/07/2026 -
Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
16/07/2026 -
A breakthrough in coronary bypass surgery: AMT Medical’s SAFE-CAB results published in The Journal of Thoracic and Cardiovascular Surgery
16/07/2026 -
Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
16/07/2026 -
InnoCare Announces Phase II Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Vitiligo
16/07/2026 -
Marius Pharmaceuticals Welcomes Department of Defense's New Testosterone Screening Initiative for U.S. Service Members
16/07/2026 -
Sonus Microsystems’ Autonomous Ultrasound AI Platform Selected for Major ARPA-H Maternal Health Award
16/07/2026 -
SRX Global Regains Full Compliance with NYSE American Listing Standards
16/07/2026 -
Arcutis Expands Board of Directors with Appointment of Chris Peetz
16/07/2026 -
Better Blend to open two new Cincinnati-area locations
16/07/2026 -
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
16/07/2026 -
BienRaíz Launches 240 mg Magnesium Glycinate Supplement, Expanding Its Daily Wellness Portfolio with Targeted Mineral Support
16/07/2026 -
Arletta Pharma Solutions Receives FDA Response Supporting the Clinical Development Program of Lybrido™ for Female Sexual Interest/Arousal Disorder in the US
16/07/2026 -
4TEEN4 Receives U.S. FDA Fast Track Designation for Invobenitug in Cardiogenic Shock
16/07/2026 -
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16/07/2026 -
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
16/07/2026
Pages